HOME >> MEDICINE >> NEWS
OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients

PORTLAND, Ore. -- Data from an ongoing study designed to explore the biologic and clinical activity of cancer immunotherapy sipuleucel-T, or Provenge, in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic disease will be presented by Oregon Health & Science University Cancer Institute researchers.

The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT). In addition, there was a trend observed in slowing the time to metastatic disease for patients who received sipuleucel-T compared with those who received placebo, but this early trend did not reach statistical significance. The findings will be presented Saturday, June 2, at 8 a.m. (CDT) at the 43rd Annual Meeting of the American Society of Clinical Oncologists (ASCO) in Chicago.

"While there was no delay in the time to PSA recurrence, we did observe a slowing in the rate of rise of serum PSA in exploratory analyses. Additional follow-up is needed to determine if this effect on PSA will translate into patient benefits," said Tomasz Beer, M.D., lead investigator, director of the Prostate Cancer Research program at the OHSU Cancer Institute; and associate professor of medicine, (hematology/medical oncology) OHSU School of Medicine.

The ongoing trial, known as P-11, is a double-blind, multi-center, randomized, placebo-controlled study involving 176 men, all of whom had prostatectomies and then had recurrent cancer as detected by a rise in the serum tumor marker, PSA. After three months of hormone therapy, 117 men received sipuleucel-T and 59 received placebo.

Sipuleucel-T was found to have a favorable safety profile. The most common side effects seen more commonly in sipuleucel-T-t
'"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
2-Jun-2007


Page: 1 2 3

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. Cancer research summaries
3. Cancer on the agenda of the Portuguese EU Council Presidency
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
6. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
7. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
8. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
9. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research
10. Cancer-fighting foods, supplements explored in day-long symposium, March 25
11. Cancer vaccine innovator honored with prestigious Florey Medal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... September 26, 2017 , ... Ron Norman, CEO of ... use the Law of Large Numbers in favor of senior, upper-level executive job candidates ... casinos, have long understood the Law of Large Numbers as a way of protecting ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., an ... its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office is ... and Jon McCormack, both of whom have creative business development methods, who are responsive ...
(Date:9/26/2017)... Galloway, N.J. (PRWEB) , ... September 26, 2017 ... ... mocktail at the shore, the John R. Elliott HERO Campaign for Designated Drivers ... Hotel & Golf Club. , Thirty-one local bars and restaurants took on the ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Founded as ... decades growing into an innovative leader in special education. In 2018, Glenholme will ... , Glenholme, formerly a world renowned horse farm for Hackney show ponies, was generously ...
(Date:9/26/2017)... ... September 26, 2017 , ... The 2017 American Academy of Cosmetic Surgery ... Fat,” revealed not only the latest about cosmetic procedures to remove and replace fat, ... cosmetic medicine. , “Fat really is magical, especially when it comes to the cosmetic ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Sapheneia and Scannerside received FDA 510(k) clearance ... a third-party Vendor neutral CT product that makes it ... with current MITA standards. ... is specifically designed to provide CT operators, prior to ... over a predefined threshold. Scannerside Dose Check is intended ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a leading ... a vibrant charitable donation program -- "Color for ... congenital heart defect research by The Children,s Heart ... the general public are encouraged to download a ... the completed artwork to the gallery on the ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
Cached News: